I'm a medical professional
The page describes how to confirm a patient received an oral device from their dentist.

SomnoMed manufactures SomnoDent sleep apnea devices for dentists with a proprietary b-flex comfort liner.
somnomed.comCrawled Nov 18, 2026
The page describes how to confirm a patient received an oral device from their dentist.
SomnoDent therapy may be as effective as CPAP for mild or moderate obstructive sleep apnea.
A SomnoMed sleep apnea oral appliance is an FDA-cleared, custom-fitted dental device specially designed to be an effective, comfortable, and durable
The page suggests verifying patient compliance and satisfaction with oral appliance therapy.
Obstructive Sleep Apnea (OSA) is a condition in which breathing stops involuntarily for brief periods of time during sleep. This is normally due to the
Enrico is the Senior Vice President for SomnoMed North America. Prior to SomnoMed, Enrico spent over 20 years in finance and operations management in the
Founded in 2004, SomnoMed is an Australian Stock Exchange listed medical device company operating in 28 countries.
SomnoMed provides oral appliance therapy for obstructive sleep apnea, offering SomnoDent devices as a CPAP alternative.
SomnoMed provides oral appliance therapy for obstructive sleep apnea, offering SomnoDent devices as a CPAP alternative.
SomnoMed - die komfortable und effektive Alternative zu CPAP bei der Behandlung von obstruktiver Schlafapnoe.
Sleep apnea occurs when relaxed tongue and throat muscles block airflow during breathing.
SomnoMed (ASX:SOM) experiences a rise in its share price. The article does not specify the exact cause, but it highlights investor interest in the healthcare company’s stock performance.
SomnoMed reports a **19% increase in EBITDA** for fiscal year 2026, driven by strong performance in **North America**. The company’s sleep-disorder diagnostics and treatment solutions see growing demand, particularly in the U.S. market. Revenue growth and operational efficiency contribute to the financial uplift, with management citing expanding customer adoption of its **Sleep Health Technology** platform.
SomnoMed reports **FY26 revenue of $114.5 million**, a 3% increase from the prior year. The company’s **EBITDA rises 19% to $10.9 million**, with margins expanding to **9.6%**, driven by North American performance.
SomnoMed introduces the Virtus, an oral appliance for obstructive sleep apnea (OSA) featuring an internal metal core designed to endure sleep bruxism (teeth grinding). The device aims to provide durability for patients who grind their teeth during sleep while addressing OSA symptoms. SomnoMed specializes in sleep-disordered breathing solutions, expanding its product line with this reinforced design.
SomnoMed (ASX:SOM) experiences volatility in its share price, fluctuating between AU$0.73 and AU$0.53 over recent months. The stock currently trades at AU$0.57, raising questions about whether its valuation reflects true market value or presents an undervaluation opportunity for investors. The company operates in an unspecified sector, with no additional operational or financial details provided in the article.